A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as retinal diseases and geographic atrophy. It designs and engineers RNAi trigger molecules, such as smaller size, novel cleavage mechanisms, and tailored targeting ligands to enhance potency, specificity, and delivery to various tissue types. Its products includes CITY-FXI, is a city-engineered n-acetylgalactosamine -conjugated small interfering RNA therapeutic targeting factor XI; CITY-RBP4, is a city-engineered GalNAc-conjugated siRNA therapeutic, in development for the treatment of Stargardt disease; CITY-TFR2, is a city-engineered GalNAc-conjugated siRNA therapeutic candidate in development for anemia of chronic disease; The company advances these therapeutics from research through clinical and commercial development stages and engages in strategic collaborations to co-develop RNAi clinical candidates. It has a strategic collaborations with Bausch + Lomb Ireland Limited and Biogen MA Inc. to advance extrahepatic RNAi therapeutics for diseases of the eye and the central nervous system. The company serves clients in the pharmaceutical, biotechnology, and life sciences industries and collaborates with organizations in the ophthalmology sector. The company was incorporated in 2023 and is based in Cambridge, Massachusetts.
Financial Summary
| Share Statistics | CTY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,033.4 | $229.7 | 46% |
|
| Shares Out (Mil) | 6.2 | 53.4 | 16% |
|
| Institutional Ownership | 60.1% | 92.9% | 39% |
|
| Float (Mil) | 27.8 | 41.7 | 34% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 516 | 520 | 59% |
|
| Price Change (52-week) |
na | 46.5% | na |
|
| Growth | CTY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CTY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $14 | $37 | 11% |
|
| Net Income (TTM) (Mil) | ($88) | ($44) | 12% |
|
| EPS (TTM) | ($15.721) | ($1.600) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($78) | ($33) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $80 | $2 | 75% |
|
| Long-Term Debt (Q1) (Mil) | $19 | $4 | 32% |
|
| Enterprise Value (Q1) (Mil) | $1,014 | $175 | 41% |
|
| Valuation | CTY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.17 | na |
|
| P/E | na | 20.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CTY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (460.3%) | 66.5% | 0% |
|
| Net Margin | (611.3%) | (75.9%) | 1% |
|
| ROA | (84.0%) | (47.2%) | 7% |
|
| ROE | 133.1% | (53.5%) | 97% |
|
| Liabilities to Assets | 40.4% | 29.4% | 31% |
|
| F-Score | 1 | 2 | na |
|
City Therapeutics, Inc. did not pass any screens on 10/23/2026.
